We describe the case of a small child with stage IV neuroblastoma who developed thrombotic thromobocytopenic purpura (TTP) post autologous bone marrow transplant. Pneumococcal sepsis may have been the cause, a previously unreported association in transplant-associated TTP. Despite the child's size (10 kg) and the severity of the disease early intensive treatment with whole blood exchange and subsequently plasma exchange with cryosupernatant proved to be rapidly effective, in contrast to previous reports on its ineffectiveness in this setting. Bone Marrow Transplantation (2000) 25, 679-680. Keywords: thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome; bone marrow transplantation; plasma exchange; cryosupernatant Case report A 2.-year-old female presented 13 days post autologous bone marrow transplant with frank haemoglobinuria, epistaxis and gastrointestinal bleeding. Six months previously she had been diagnosed as having stage IV neuroblastoma and had been randomised to the ENSG 5 trial. She had received seven courses of chemotherapy (vincristine, cyclophosphamide, etoposide and alternate carboplatin/cisplatin, ie alternating OPEC/OJEC), followed by definitive tumour excision and autologous bone marrow transplantation. Conditioning was with melphalan 200 mg/m 2 following priming with cyclophosphamide 300 mg/m 2 . She received 650 ml of autologous bone marrow with a total CD34 count of 4 × 10 6 /kg. The transplant was uncomplicated until she developed a pneumococcal septicaemia on day +10 manifest by a febrile episode and positive cultures. This resolved rapidly with prompt antibiotic therapy, initially with genta-
A 2.-year-old female presented 13 days post autologous bone marrow transplant with frank haemoglobinuria, epistaxis and gastrointestinal bleeding. Six months previously she had been diagnosed as having stage IV neuroblastoma and had been randomised to the ENSG 5 trial. She had received seven courses of chemotherapy (vincristine, cyclophosphamide, etoposide and alternate carboplatin/cisplatin, ie alternating OPEC/OJEC), followed by definitive tumour excision and autologous bone marrow transplantation. Conditioning was with melphalan 200 mg/m 2 following priming with cyclophosphamide 300 mg/m 2 . She received 650 ml of autologous bone marrow with a total CD34 count of 4 × 10 6 /kg. The transplant was uncomplicated until she developed a pneumococcal septicaemia on day +10 manifest by a febrile episode and positive cultures. This resolved rapidly with prompt antibiotic therapy, initially with genta- On day +12 she had minor gastrointestinal bleeding associated with a rising serum bilirubin to 69 mol/l. Within 24 h, she was drowsy, had frank haemoglobinuria, a bloody nasogastric aspirate, epistaxis and loose, bloody stools and developed repetitive arm movements. Laboratory parameters demonstrated a falling haemoglobin (104 g/1 to 87 g/1), falling platelet count (56 × 10 9 /1 to 32 × 10 9 /1), rising urea (5.4 mmol/1 to 7.3 mmol/l) and creatinine (47 mol/1 to 57 mol/l). There was marked red cell fragmentation on the blood film. Coagulation was normal. A serum lactate dehydrogenase (LDH) was 3980 U/l. A diagnosis of thrombotic thrombocytopenic purpura secondary to bone marrow transplantation and pneumococcal sepsis was made. Over the next 12 h she became progressively more hypertensive with a blood pressure of 130/90 mm Hg requiring treatment with hydralazine and subsequently labetalol infusion. By day +14 she was obtunded (GCS 11) and frankly haemorrhagic indicating the need for therapeutic intervention.
In view of the problems associated with the child's size (10 kg) and venous access initial treatment was with daily manual whole blood volume exchange (800 ml) with leucocyte-depleted whole blood. This resulted in a fall in LDH to 3123 U/l, but no clinical improvement. On day +18 after insertion of a Quentin line we were able to perform a plasma exchange with two volumes of cryosupernatant using a Cobe cell separator with a whole blood prime. This produced immediate improvements in blood pressure control and by 12 h she was alert and speaking appropriately. Daily plasma exchanges with cryosupernatant continued until day +32 when her serum LDH had normalised and there was no evidence of fragmentation on the blood film. It was stopped at day +34 (see Figure 1) .
She continued to haemorrhage significantly throughout this period necessitating alternate day platelet transfusions despite our strong reservations on their use in this condition. Although her neurological improvement was sustained, she continued to have significant problems with hypertension and fluid overload secondary to left ventricular dysfunction for which she required continuous venovenous haemofiltration from day +25 until day +41. until day +40 despite the use of GCSF to day +35 and subsequently GMCSF in accordance with EBMT guidelines.
At 3 months post transplant our patient was well with no disease sequelae evident. She remained thrombocytopenic, but had no neurological problems and was dialysis independent. Her improvement was sustained and by 6 months she had achieved appropriate developmental milestones for age. Unfortunately she died 1 year post transplant from relapsed neuroblastoma. There was no evidence of relapse of TTP during this period.
Discussion
Thrombotic thrombocytopenic purpura (TTP) is often a difficult diagnosis in the setting of bone marrow transplantation. Many patients experience renal impairment or altered sensorium and most are thrombocytopenic or febrile secondary to other causes. Microangiopathic changes are frequently found post transplant in the absence of TTP or other established causes of red cell fragmentation. 1 TTP is increasingly reported after allogeneic, and more recently autologous, bone marrow transplant. [1] [2] [3] The most likely pathogenesis is widespread endothelial damage resulting from high-dose chemotherapy and /or radiotherapy, cyclosporin administration, graft-versus-host-disease (GVHD), cytomegalovirus infection and veno-occlusive disease (VOD).
1 Bacterial infection has not been reported as a cause of post-transplant TTP, although classical TTP/HUS is commonly associated with ST verotoxin produced by shigella and E. coli species and has been reported in pneumococcal septicemia. 4 Endothelial damage probably allows the release of unusually high molecular weight von Willebrand factor (vWF) multimers which have an increased affinity for platelet receptors at high shear stress levels leading to widespread microvascular thrombosis. These large multimers are proteolysed in normal conditions, but in TTP there appears to be an absence of vWF cleaving protease or a protease inhibitor which prevents this. 5, 6 Cyclosporin is the most important cause of post-tranplant TTP;
1 it causes direct endothelial damage and produces a concentration dependent increase in vWF release. Radiation can cause endothelial damage and is implicated in 95% of cases of post-transplant TTP. 1 However, the association with GVHD and VOD has led to suggestions that a cytokine release cascade after endothelial damage may in part be responsible and that these represent different reactions to a common endothelial insult. There is no direct evidence implicating cyclophosphamide in endothelial cell damage. 3 Despite the similarities in the clinical and laboratory presentation of classical TTP and post-transplant TTP, there is no evidence for a deficiency of a plasma factor in transplant-associated TTP and plasma exchange with fresh frozen plasma (FFP) has classically proved disappointing in this setting with mortality rates of 84%.
1 Transplantassociated TTP is classically treated late because of the difficulties in making the diagnosis and this may in part be responsible for the traditionally high mortality. The use of cryosupernatant as the exchange fluid is more promising. Byrnes et al 7 reported treatment successes in a series of seven patients with classical TTP who had failed to respond to standard treatment with FFP and further work by The Canadian Apheresis Group 8 confirmed these findings with a 95% 1 month survival. Several reports have looked at this therapy in transplant-associated TTP -in 23 patients with high risk disease treated with plasma exchange with cryosupernatant with or without immunoadsorbtion the mortality rate appears to be much lower at 52%.
